Immuno-oncology startup Stipe, based on Aarhus research, has secured $22m in a round co-led by Novo Seeds, after being incubated at Novo's BioInnovation Institute.
Stipe Therapeutics, a Denmark-based immuno-oncology drug developer spun out of Aarhus University, has raised €20m ($22m) in a series A round co-led by Novo Seeds, the company creation arm of pharmaceutical company Novo.
The round was co-led by life sciences investment firm Arix Bioscience and included Wellington Partners’ Life Science Venture Capital Management fund and Sunstone Life Science Ventures.
Spun out of Aarhus University’s Department of Biomedicine in 2018, Stipe is working on treatments for tumours and autoimmune…
